Prophylactic Medication during Radioembolization in Metastatic Liver Disease: Is It Really Necessary? A Retrospective Cohort Study and Systematic Review of the Literature.

ABSTRACT:

Purpose

Trans-arterial radioembolization is a well-studied tumoricidal treatment for liver malignancies; however, consensus and evidence regarding periprocedural prophylactic medication (PPM) are lacking.

Methods

A single-center retrospective analysis from 2014 to 2020 was performed in patients treated with ⁹⁰Y-glass microspheres for neuroendocrine or colorectal liver metastases. Inclusion criteria were the availability of at least 3 months of clinical, biochemical, and imaging follow-up and post-treatment ⁹⁰Y-PET/CT imaging for the determination of the whole non-tumorous liver absorbed dose (D_h). Logistic regression models were used to investigate if variables (among which are P/UDCA and D_h) were associated with either clinical to

SUBMITTER: Braat MNGJA 

PROVIDER: S-EPMC10742749 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature